Scanning people with multiple myeloma using a fluciclovine PET/CT imaging test
Tests a fluciclovine PET/CT scan in adults with multiple myeloma, a blood cancer.
Key facts
- Who runs it
- Oslo University Hospital HF
- Where
- Oslo, NorwaySee the site
- Registry title
- Imaging multiple myeloma patients in the REMNANT study with Fluciclovine PET/CT (FLUCIPET)
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 50 people, planned
- Started
- 18 Dec 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 27 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma who are already in the REMNANT study Part 2 and can have an FDG PET/CT scan. They will also have a Fluciclovine PET/CT scan.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma, in people already enrolled in the REMNANT study Part 2.
Main reasons for not taking part
- Does not sign the consent or does not accept the study premises
- Hypersensitivity to the active substance or to any of the excipients
- Kidney problems where extra radiation is possible and the added risk is not acceptable
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients who have been enrolled in the REMNANT study Part 2 and who are eligible for FDG PET/CT
Who cannot take part
- Hypersensitivity to the active substance or to any of the excipients
- Patients with renal impairment for whom an increased radiation exposure is possible, and the additional potential risk is considered not acceptable
- Patients who do not sign the consent for any reason or do not accept the study premises
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Norway
- Oslo University Hospital HFOslo, NorwayTaking people
About the trial
What the trial wants to find out
To detect the number of patients in the REMNANT study who are positive with Fluciclovine PET/CT and negative with FDG PET/CT and determine how this correlate to PFS and OS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Imaging multiple myeloma patients in the REMNANT study with Fluciclovine PET/CT (FLUCIPET)
- Plain-language title
- Scanning people with multiple myeloma using a fluciclovine PET/CT imaging testGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-517095-38-00, who can take part
- Record updated
- 27 May 2025